cepharanthine has been researched along with Colorectal Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boonkrai, C; Limpanasittikul, W; Mutirangura, A; Payon, V; Rattanawong, A; Wonganan, P | 1 |
| Kongsaden, C; Unson, S; Wonganan, P | 1 |
2 other study(ies) available for cepharanthine and Colorectal Cancer
| Article | Year |
|---|---|
Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1.
Topics: Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Mutation; Tumor Suppressor Protein p53; Up-Regulation | 2018 |
Cepharanthine combined with 5-fluorouracil inhibits the growth of p53-mutant human colorectal cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzylisoquinolines; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Molecular Structure; Neoplasm Proteins; Tumor Suppressor Protein p53 | 2020 |